drugset
drugset / Trial / NCT02003534

A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension

NCT02003534 ↗

Phase 4 Completed 376 enrolled Allergan
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate 0.15% brimonidine tartrate in patients with primary open angle glaucoma and ocular hypertension.

Timeline

Start
2010-07
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule 0.15 % Other

Indications

ocular hypertension open-angle glaucoma